• The Roald Dahl Haemostasis and Thrombosis Centre is only 26 nationally accredited Haemophilia Comprehensive Care Centres. The Centre is a Reference Centre for the Merseyside and North Wales region, taking referrals from across the whole area for patients with bleeding disorders.

    Lead: The Roald Dahl Haemostasis and Thrombosis Centre

    Contact: Tel: 0151 706 2000

  • The Royal has the main Emergency Department for the city of Liverpool, the largest of its kind in the country, with the ability to treat major, complex trauma (it is a designated major trauma centre) as well as minor injuries.

  • St Paul’s Eye Unit provides a world renowned ophthalmic service not only to the local community of Liverpool, but also nationally and worldwide.

  • Broadgreen Hospital has a rehabilitation unit, which is part of the Merseyside rehabilitation network.

  • The Royal has the regional bone marrow unit providing care for patients across Merseyside and Cheshire.

  • The Trust has the only dedicated centre in the world for the treatment of ultra rare disease Alkaptonuria.

  • The Trust has a specialist infectious and tropical diseases unit at the Royal.


  • The Royal is the biggest hospital trust in Merseyside and Cheshire, providing specialist care, complex treatment and routine care for patients across Merseyside, Cheshire and beyond.

    The Trust has a number of services it provides on a regional or national level.

  • The Royal is the regional renal transplant centre for Merseyside and Cheshire

  • The Trust have the only tropical diseases unit in Merseyside and Cheshire.

  • The Trust provides 11 regional cancer services, including bone marrow transplants, pancreatic cancer surgery, urological cancer and testicular cancer.

  • The Trust is a national centre for ocular oncology and the north Mersey centre for complex vascular surgery.

  • The Trust is the host organisation for the North West Coast Comprehensive Research Network

  • The Trust is a designated major trauma centre, part of the Merseyside and Cheshire Collaborative.

  • The Trust is a leading centre for trauma and orthopaedics.

  • The Trust is an international centre for the treatment of rare disease Alkaptonuria.

  • The Trust has the only dental hospital in Merseyside and Cheshire and is a specialist centre for interventional radiology and nuclear medicine.

  • The Trust houses a rehabilitation facility at Broadgreen Hospital as part of the Merseyside and Cheshire rehabilitation network.


The Trust undertake the highest number of clinical trials and research studies in the North West Coast with around 400 on-going trials each year, with thousands of patients a year benefiting from research


  • The CRU was opened in 2009 and provides state of the art dedicated facilities to support high quality clinical research both in an inpatient and outpatient setting. The CRU is a resource open to researchers from all disciplines encouraging collaboration with investigators in Liverpool, Merseyside, and beyond.

    The CRU is managed by the CRU Operations Group who are able to provide expertise and guidance in study set-up to researchers using the Clinical Research Unit

    Lead: CRU Operations Group Chair - Mrs Jules West Operational Director RD&I

    Contact: Tel: 0151 706 3756

  • The CRU became the first NHS facility in England to be granted MHRA (Medicines and Healthcare products Regulatory Agency) standard and supplementary Phase I Accreditation. The accreditation means the Royal has the first NHS clinical research unit in England that meets the high standards required for early clinical trials. This is where drugs or other treatments are tested on humans for the first time as part of tightly controlled research projects.

    Lead: Dr Richard Fitzgerald, Director of the CRU

    Contact: Tel 0151 706 4861

  • The NIHR Pancreatic Biomedical Research Unit  (PRBU) is housed at the Royal. It is a leading global translational research unit dedicated to the management of pancreatic digestive diseases, such as acute and chronic pancreatitis and pancreatic cancer. The PBRU is the premier centre in the UK and one of the top three centres in Europe, carrying out translational research into pancreatitis and pancreatic cancer.

    Lead: Professor Robert Sutton, Executive Director

    Contact: Tel 0151 706 4877

  • The Trust has a Strategic Alliance (NHS/Commercial Partnership) with a leading drug development company global company Covance to carry out early stage clinical research trials. This alliance provides a unique opportunity to build innovative solutions for high-quality early clinical research in a safe and regulated environment.

    Lead: Mrs Jules West, Operational Director RD&I

    Contact: Tel: 0151 706 3756

  • The Royal's RD&I department successfully developed a new ground-breaking clinical trial recruitment system called Consent for Consent within the Trust. The RD&I department is a central corporate function within the Trust. There are around 400 clinical trials and studies per year in the Trust. The department, in collaboration with the University of Liverpool, supports the development of high quality research and innovation within the Royal Liverpool University Hospital.

    Lead: Professor Robert Sutton, Clinical Director RD&I & Mrs Jules West Operational Director RD&I

    Contact: Tel: 0151 706 3756

  • Following investment by the Trust of £900K and £200K from Liverpool Health Partners the Trust has established a Liverpool Biomedical Research Centre in Personalised Health is focussed on developing new diagnostics and treatments for Cancer Drugs, Infection and Inflammmation. it will bridge the gap across fundamental discovery science and clinical application.

    Lead: Professor Robert Sutton, Executive Director

    Contact: tel 0151 706 3756 



  • The Trust has the only daVinci robotic surgical system in Liverpool surgery on patients suffering from prostate, bladder and kidney cancer. This has significantly reduced recovery time for those patients and improved the experience of our patients.

  • The Trust have one of very few Flash-CT scanners in the north-west. It is one of the fastest scanners available and can be used for all routine diagnostic imaging procedures, such as orthopaedic, oncology, neurology, gastrointestinal, vascular and interventional patients. It has a specialised function for cardiac patients, severely traumatised or unconscious patients, children and patients for whom holding their breath is difficult, improving the experience of our patients.

  • The Trust have the first PET-CT static scanner in Merseyside and Cheshire. The £1.8 million state of the art scanner is used to diagnose certain types of cancer and other diseases. It helps personalise and tailor treatment to individual patients. It is used as part of a number of research projects and trials.


  • As a major university hospital, The Royal has close relationships with the University of Liverpool, Liverpool John Moores University and the Liverpool School of Tropical Medicine, with student nurses, student dentists, medical students and others all undertaking placements at our hospitals.
  • In 2013, The Trust entered into a five-year exclusive agreement to work together with international drugs development company Covance in conducting early clinical trials at the Royal on behalf of biotechnology and pharmaceutical companies. This is one of only two such agreements in the NHS and means.


  • The Trust have a commercial agreement to work with drug development company Redx Pharma on new drugs to combat the threat of antibiotic resistance.
  • The Trust have a commercial agreement to work with drug development company Redx Pharma on new drugs to combat the threat of antibiotic resistance. The collaboration is one of the very first commercial agreements to deliver on a stated aim of NHS England to develop more partnerships with industry. In a collaboration that runs until September 2016, Redx and the Royal are set to bring this aspiration to life. Under the terms of the agreement, Redx will provide discovery and development expertise across its bases in Liverpool and Alderley Park, Cheshire, while the Royal is to utilise its extensive clinical development capabilities.
  • The Trust work closely with the Liverpool University Technical College for Life Sciences, with students coming to the Royal for work placements. Staff from the Royal worked on the curriculum for students with the UTC.


  • The Trust currently runs trials across 39 different clinical specialties and has expertise in all areas.


  • The brand new £429m Royal Liverpool University Hospital will open to patients in 2017, with work beginning on site in February 2014. The facility will be state of the art, with all single bedrooms for patients.
  • There are plans to develop the Liverpool BioCampus on the same site as the new Royal (once the current building is demolished), which is a unique opportunity to place Liverpool on the world life sciences stage alongside Boston and Singapore.
  • Several services have moved from the Royal to Broadgreen Hospital, including most urology services, dermatology and some orthopaedics. The Royal will be the centre for specialist and emergency care and Broadgreen the elective care and rehabilitation centre.



  • Won Team of the Year from the Nursing Times in 2012 for safeguarding adults.
  • The Royal has the only NIHR biomedical research unit dedicated to pancreatic diseases in the UK.
  • The Royal is the first NHS facility in England and Wales to carry out first in human drug trials after winning accreditation from the MHRA.
Royal Liverpool University Hospital
Prescot Street
L7 8XP


Staff 5500
In patients 89914
Out patients 574827
Beds 770
A&E 87861
Go Back

Sign up for our newsletter


Sign up to receive our free, quarterly e-mail newsletter for news and information from LHP

We won’t use your details for any other purpose, and we won’t pass them on to any other organisation.